Tarsus Pharmaceuticals Inc (TARS) - Total Assets
Based on the latest financial reports, Tarsus Pharmaceuticals Inc (TARS) holds total assets worth $611.14 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Tarsus Pharmaceuticals Inc - Total Assets Trend (2018–2025)
This chart illustrates how Tarsus Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see market value of Tarsus Pharmaceuticals Inc for the company's overall valuation and market capitalisation.
Tarsus Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Tarsus Pharmaceuticals Inc's total assets of $611.14 Million consist of 93.0% current assets and 7.0% non-current assets. Review Tarsus Pharmaceuticals Inc total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 32.7% |
| Accounts Receivable | $87.11 Million | 15.5% |
| Inventory | $4.37 Million | 0.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $7.37 Million | 1.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Tarsus Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Tarsus Pharmaceuticals Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tarsus Pharmaceuticals Inc's current assets represent 93.0% of total assets in 2025, a decrease from 99.8% in 2018.
- Cash Position: Cash and equivalents constituted 32.7% of total assets in 2025, down from 98.6% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 15.5% of total assets.
Tarsus Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Tarsus Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Tarsus Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.20 | 5.26 | 18.05 |
| Quick Ratio | 3.17 | 5.21 | 18.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $386.24 Million | $384.18 Million | $176.72 Million |
Tarsus Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Tarsus Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.05 |
| Latest Market Cap to Assets Ratio | 6.11 |
| Asset Growth Rate (YoY) | 49.1% |
| Total Assets | $562.16 Million |
| Market Capitalization | $3.43 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Tarsus Pharmaceuticals Inc's assets at a significant premium (6.11x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Tarsus Pharmaceuticals Inc's assets grew by 49.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Tarsus Pharmaceuticals Inc (2018–2025)
The table below shows the annual total assets of Tarsus Pharmaceuticals Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $562.16 Million | +49.12% |
| 2024-12-31 | $376.99 Million | +42.00% |
| 2023-12-31 | $265.49 Million | +16.51% |
| 2022-12-31 | $227.86 Million | +27.36% |
| 2021-12-31 | $178.91 Million | +4.03% |
| 2020-12-31 | $171.97 Million | +194.90% |
| 2019-12-31 | $58.32 Million | +2341.02% |
| 2018-12-31 | $2.39 Million | -- |
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as we… Read more